

A Mathematical Model Investigating the Impact of an Environmental Reservoir on the

Prevalence and Control of Vancomycin-Resistant Enterococci

Author(s): Emma S. McBryde and Donald L. S. McElwain

Source: The Journal of Infectious Diseases, Vol. 193, No. 10 (May 15, 2006), pp. 1473-1474

Published by: Oxford University Press

Stable URL: https://www.jstor.org/stable/30086574

Accessed: 21-02-2020 02:58 UTC

### REFERENCES

Linked references are available on JSTOR for this article: https://www.jstor.org/stable/30086574?seq=1&cid=pdf-reference#references\_tab\_contents You may need to log in to JSTOR to access the linked references.

JSTOR is a not-for-profit service that helps scholars, researchers, and students discover, use, and build upon a wide range of content in a trusted digital archive. We use information technology and tools to increase productivity and facilitate new forms of scholarship. For more information about JSTOR, please contact support@jstor.org.

Your use of the JSTOR archive indicates your acceptance of the Terms & Conditions of Use, available at https://about.jstor.org/terms



Oxford University Press is collaborating with JSTOR to digitize, preserve and extend access to  $\it The Journal of Infectious Diseases$ 

CMV DNA in CSF from patients with GBS will have to be elucidated further in future studies. Even more importantly, the clinical significance of CMV DNA present in CSF has to be investigated, particularly to clarify whether these patients should be offered antiviral therapy.

## Christoph Steininger<sup>1,2</sup> and Elisabeth Puchhammer-Stöckl<sup>2</sup>

<sup>1</sup>Department of Internal Medicine I and <sup>2</sup>Institute of Virology, Medical University of Vienna, Vienna, Austria

#### References

- Kuijf ML, Ang CW, van Doorn PA, Niesters HGM, Jacobs BC. Presence or absence of cytomegalovirus in cerebrospinal fluid from patients with Guillain-Barré syndrome [letter]? J Infect Dis 2006; 193:1471–2 (in this issue).
- van der Meché FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med 1992; 326:1123–9.
- van Koningsveld R, Schmitz PI, van der Meché FG, Visser LH, Meulstee J, van Doorn PA. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Dutch Guillain-Barré Study Group. Lancet 2004; 363:192–6.
- 4. Steininger C, Popow-Kraupp T, Seiser A, Gueler N, Stanek G, Puchhammer E. Presence of cytomegalovirus in cerebrospinal fluid of patients with Guillain-Barré syndrome. J Infect Dis **2004**; 189:984–9.
- Alberola J, Tamarit A, Igual R, Navarro D. Early neutralizing and glycoprotein B (GB)-specific antibody responses to human cytomegalovirus (HCMV) in immunocompetent individuals with distinct clinical presentations of primary HCMV infection. J Clin Virol 2000; 16:113–22.
- 6. Zipeto D, Hong C, Gerna G, et al. Geographic and demographic differences in the frequency of human cytomegalovirus GB genotypes 1–4 in immunocompromised patients. AIDS Res Hum Retroviruses **1998**; 14:533–6.
- Steininger C, Schmied B, Sarcletti M, Geit M, Puchhammer-Stockl E. Cytomegalovirus genotypes present in cerebrospinal fluid of HIVinfected patients. AIDS 2005; 19:273–8.

Potential conflicts of interest: none reported.

Reprints or correspondence: Dr. Christoph Steininger, Medical University of Vienna, Dept. of Internal Medicine I, Div. of Infectious Diseases, Waehringer Guertel 18-20, A-1090 Vienna, Austria (christoph.steininger@meduniwien.ac.at).

**The Journal of Infectious Diseases 2006; 193:1472–3** © 2006 by the Infectious Diseases Society of America. All rights reserved. 0022-1899/2006/19310-0020\$15.00

# A Mathematical Model Investigating the Impact of an Environmental Reservoir on the Prevalence and Control of Vancomycin-Resistant Enterococci

To the Editor—In an article recently published in the *Journal of Infectious Diseases*, D'Agata et al. [1] presented a mathematical model of the transmission of vancomycin-resistant enterococci (VRE). We developed an extension of that model that incorporates an environmental reservoir for VRE. Although our model (which we call the "environment model") supports many of the findings of D'Agata et al., we predict different outcomes for some infection-control interventions.


VRE is known to contaminate environmental surfaces [2, 3], and case-control studies have suggested that such contamination can contribute to the acquisition of VRE [4]. This had led many researchers to speculate that the environment plays an important role in patient acquisition of VRE.

Mathematical models can give insight into the likely consequences of infection-control practices, such as hand hygiene [5, 6], patient cohorting [5, 6], staff-to-patient ratios [7], and antibiotic restriction [1]. However, mathematical models will only deliver results based on the assumptions underlying them. All models that have been published to date on the nosocomial transmission of VRE have assumed that there is no transmission due to environmental contamination. It is important to estimate how environmental contamination could influence the outcomes of infection-control interventions.

The environment model uses the structure and assumptions of the model presented by D'Agata et al. and adds a new environment compartment. It is assumed that the environment is saturable and that colonized patients and health-care workers contribute to environmental contamination. In turn, the contaminated environment can cause the contamination of health-care workers, indirectly leading

to patient colonization. The new model requires the addition of 4 parameters:  $\beta_{eh}$  (0.15), transmission from health-care workers to the environment;  $\beta_{e0}$  (0.4), transmission from colonized patients not exposed to antibiotics to the environment;  $\beta_{e1}$  (4), transmission from colonized, antibiotic-exposed patients to the environment; and  $\kappa$  (0.1), the rate of decontamination of the environment. Parameters were chosen so that the rate of environmental contamination was 25% that of patient or health-care worker contamination. In accordance with the findings of Wendt et al. [8] and Noskin et al. [9] that VRE persists in the environment for at least 1 week, we assumed that VRE persists for an average of 10 days in the environment. To make the equilibrium colonization prevalence the same as that of D'Agata et al., the "fitted" parameter,  $\beta_{p1}$ , was 0.0074 in our model. All other parameters were those of D'Agata et al.

Our model predicted that, in the presence of an environmental reservoir, the direction of the impact of infection-control interventions is the same as the predictions in the model of D'Agata et al. (which we call the "original model") but that the magnitude is altered. The environment model predicts that improving hand-hygiene compliance from 40% to 60% leads



**Figure 1.** Model predictions of the prevalence of vancomycin-resistant enterococci (VRE) over time. Both the environment and the original model begin with VRE at an endemic steady-state level of 12%. On day 200, further colonized patients are prevented from entering the ward. In the environment model, a new equilibrium is established at 5.3%.

### **Equations**

$$\begin{split} &\frac{dP_{u0}}{dt} = \Delta_{u0} + \sigma_{u1}P_{u1} - (\tau_{u0} + \gamma_{u0})P_{u0}\,, \\ &\frac{dP_{u1}}{dt} = \Delta_{u1} - (\sigma_{u1} + \gamma_{u1})P_{u1} + \tau_{u0}P_{u0} - \left[\alpha_{p1}\beta_{p1}(1-\eta)\frac{H_c}{N_b}\right]P_{u1}\,, \\ &\frac{dP_{c0}}{dt} = \Delta_{c0} + \sigma_{c1}P_{c1} - (\tau_{c0} + \gamma_{c0})P_{c0}\,, \\ &\frac{dP_{c1}}{dt} = \Delta_{c1} - (\sigma_{c1} + \gamma_{c1})P_{c1} + \tau_{c0}P_{u0} + \left[\alpha_{p1}\beta_{p1}(1-\eta)\frac{H_c}{N_b}\right]P_{u1}\,, \\ &\frac{dH_u}{dt} = \left[-\alpha_{p0}\rho\beta_{h0}\frac{P_{c0}}{N_p} - \alpha_{p1}\rho\beta_{h1}\left(\frac{P_{c1}}{N_p} + E\right)\right](N_h - H_c) + \mu H_c\,, \\ &\frac{dE}{dt} = \left(\beta_{c0}\frac{P_{c0}}{N_p} + \beta_{c1}\frac{P_{c1}}{N_p} + \beta_{ch}\frac{H_c}{N_h}\right)(1-E) - \kappa E\,. \end{split}$$

to a reduction in admission prevalence of 17% for the environment model, compared with 23% for the original model. Increasing staff-to-patient ratios from 1:4 to 1:2 leads to a reduction in colonization prevalence of 24% for the environment model, compared with 32% for the original model. Reducing the length of stay of colonized patients from 28 to 14 days led to a reduction in colonization prevalence of 51% for the environment model and 64% for the original model. The selective isolation of colonized patients (under the presumption of 80% efficacy) led to a predicted 44% reduction in colonization prevalence for the environment model, compared with 42% reduction for the original model.

A significant prediction of the environment model is that, even if colonized patients are prevented from entering the ward, VRE remains endemic at a rate of 5.3%, as illustrated in figure 1. This differs from the conclusion of D'Agata et al. The system of ordinary differential equations governing this model is as follows.

The model predicts that the presence of an environmental reservoir reduces the predicted efficacy of some interventions (e.g., compliance with hand hygiene, increased staffing levels, and reduced length of stay) yet increases the predicted efficacy of others (selective isolation). The results of the model with regard to different effects due to interventions are not intuitively obvious. We show that, under certain circumstances, an environmental reservoir for VRE could lead to endemic VRE transmission even if the admission of

VRE-colonized patients ceases. These results suggest that, in the presence of an environmental reservoir, VRE may be harder to eradicate and infection-control interventions less effective, with the exception of patient isolation, which remains effective, as predicted by this model.

The system of ordinary differential equations describing the environment model is shown. Please see D'Agata et al. [1] for an explanation of parameters not given in the text.

## Emma S. McBryde<sup>1,2</sup> and Donald L. S. McElwain<sup>1</sup>

School of Mathematical Sciences, Queensland University of Technology, and <sup>2</sup>Department of Infectious Diseases, Royal Brisbane and Women's Hospital, Melbourne, Australia

### References

- D'Agata EMC, Webb G, Horn M. A mathematical model quantifying the impact of antibiotic exposure and other interventions on the endemic prevalence of vancomycin-resistant enterococci. J Infect Dis 2005; 192:2004–11.
- Bonten MJ, Hayden MK, Nathan C, et al. Epidemiology of colonisation of patients and environment with vancomycin-resistant enterococci. Lancet 1996; 348:1615–9.
- Smith TL, Iwen PC, Olson SB, Rupp ME. Environmental contamination with vancomycinresistant enterococci in an outpatient setting. Infect Control Hosp Epidemiol 1998; 19:515–8.
- 4. Martinez JA, Ruthazer R, Hansjosten K, Barefoot L, Snydman DR. Role of environmental contamination as a risk factor for acquisition of vancomycin-resistant enterococci in patients treated in a medical intensive care unit. Arch Intern Med 2003; 163:1905–12.
- Austin DJ, Bonten MJ, Weinstein RA, Slaughter S, Anderson RM. Vancomycin-resistant enterococci in intensive-care hospital settings: trans-

- mission dynamics, persistence, and the impact of infection control programs. Proc Natl Acad Sci USA **1999**; 96:6908–13.
- Cooper BS, Medley GF, Scott GM. Preliminary analysis of the transmission dynamics of nosocomial infections: stochastic and management effects. J Hosp Infect 1999; 43:131–47.
- Austin DJ, Bonten MJ. Vancomycin-resistant enterococci in intensive care hospital settings. Mem Inst Oswaldo Cruz 1998: 93:587–8.
- Wendt C, Wiesenthal B, Dietz E, Ruden H. Survival of vancomycin-resistant and vancomycin-susceptible enterococci on dry surfaces. J Clin Microbiol 1998; 36:3734–6.
- Noskin GA, Bednarz P, Suriano T, Reiner S, Peterson LR. Persistent contamination of fabric-covered furniture by vancomycin-resistant enterococci: implications for upholstery selection in hospitals. Am J Infect Control 2000; 28: 311–3.

Potential conflicts of interest: none reported

Financial support: National Health and Medical Research Council (scholarship 290541 to E.S.M.).

Reprints or correspondence: Dr. Emma S. McBryde, 111 Barry St., Carlton, Melbourne, Victoria 3010, Australia (e.mcbryde@out.edu.au).

**The Journal of Infectious Diseases 2006;193:1473–4** © 2006 by the Infectious Diseases Society of America. All rights reserved. 0022-1899/2006/19310-0021\$15.00